Streetbeat News

Price Targets

ALGN

Goldman Sachs analyst Nathan Rice has maintained a Neutral rating on Align Tech (NASDAQ:ALGN) and raised the price target from $343 to $393.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 12:53 pm

RUSHA

Credit Suisse analyst Jamie Cook maintains a Neutral rating on Rush Enterprises (NASDAQ:RUSHA) and raises the price target from $63 to $65.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:51 pm

ASGN

Credit Suisse analyst Kevin Mcveigh has reiterated an 'Underperform' rating on ASGN (NYSE:ASGN) and maintained a $60 price target.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:50 pm

TMHC

Credit Suisse analyst Dan Oppenheim maintains an Outperform rating on Taylor Morrison Home (NYSE:TMHC) and raises the price target from $47 to $56.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:49 pm

MPWR

Oppenheimer analyst Rick Schafer maintains an Outperform rating on Monolithic Power Systems (NASDAQ:MPWR) and raises the price target from $475 to $565.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 27, 2023 | 12:49 pm

TROX

Credit Suisse analyst John Roberts has maintained an 'Underperform' rating on Tronox Holdings (NYSE:TROX) and raised the price target from $10 to $12.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:49 pm

TNET

Credit Suisse analyst Kevin Mcveigh has reiterated a Neutral rating on Trinet Group (NYSE:TNET) and maintained a price target of $87.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:48 pm

FI

Credit Suisse analyst James Wicklund maintains an Outperform rating on Fiserv (NYSE:FI) and raises the price target from $135 to $140.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:47 pm

C

CB

Citigroup analyst Michael Ward has maintained a 'Buy' rating on Chubb (NYSE:CB) and raised the price target from $229 to $235.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 27, 2023 | 12:47 pm

AMED

Credit Suisse analyst Jonathan Yong has reiterated a Neutral rating on Amedisys (NASDAQ: AMED) and maintained a price target of $101.

Portfolio Pulse from richadhand@benzinga.com

July 27, 2023 | 12:46 pm